Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Why Gilead Stock Is a Sleepy Giant Waiting to Break Out

By Chris Lau, InvestorPlace Contributor

Impatient investors are waiting for Gilead stock to break out, but that will not happen right away. As Gilead develops its pipeline, however, GILD stock will rebound.

Bluebird Bio Stock May Have Upside of at Least 60 Percent

By Chris Lau, InvestorPlace Contributor

Bluebird Bio stock fell in the first week of September without reason. When the market notices its growth potential, the BLUE stock could rally.

5 Small-Cap Stocks for Investors Who Can Handle Risk

By Chris Lau, InvestorPlace Contributor

Even with markets at all-time highs, some small-cap stocks are down. But these small caps are high-risk stocks with possible high rewards.

Tandem Diabetes Is Firing on All Cylinders

By Chris Lau, InvestorPlace Contributor

Tandem Diabetes sold shares of TNDM stock, but Tandem Diabetes stock continued to rocket higher. TNDM's Q2 results impressed investors, but its seasonally strong Q4 earnings could wow them more.

Weibo Still Has Plenty of Growth Ahead

By Chris Lau, InvestorPlace Contributor

Weibo continues to attract more users to its site. Its focus on the way the user engages with the content and its creator should pay off for WB stock.

Arrowhead Stock Is Not Done Rallying After Its 38% Jump

By Chris Lau, InvestorPlace Contributor

Yesterday, Arrowhead's clinical data results excited shareholders, but ARWR stock still has plenty of upside ahead.

New Development Partnership Could Pay Off Big for MannKind Stock

By Chris Lau, InvestorPlace Contributor

MannKind scored a collaboration deal with biotechnology giant, United Therapeutics. This development partnership could pay off big.

Tesla Stock Will Not Survive If Market Crashes

By Chris Lau, InvestorPlace Contributor

Bears are enjoying the drop in TSLA stock and could reap in more gains if uncertainties continue to roll in.

Risks Are Still High for Investors in Ambarella Stock

By Chris Lau, InvestorPlace Contributor

Ambarella reported a weak second quarter and lowered its outlook. AMBA has strong technology advances but still needs revenues to increase.

Aveo Stock Breaks Out After Strong Drug Results and a Modest Offering

By Chris Lau, InvestorPlace Contributor

Markets are already betting that Aveo Pharmaceuticals will not seek additional capital. Aveo stock is rallying and still has more room to run.

Load More